News

Johnson & Johnson Showcases New Data for TECNIS™ IOLs at ESCRS 2025

j&j medtech logo

Accepted abstracts explore the latest advancements in Johnson & Johnson’s intraocular lens (IOL) technology, showing consistent visual outcomes across a wide range of patient profiles.1-4

4 September 2025 -- Johnson & Johnson, a global leader in eye health, announced today its upcoming data presentations and onsite activities at the 2025 European Society of Cataract and Refractive Surgeons (ESCRS) 43rd Congress, taking place from 12-16 September in Copenhagen, Denmark. The company will unveil new data highlighting the TECNIS IOL platform’s strong performance across diverse patient needs – further cementing its position as a leader in IOL lens technology.

“We’re proud to share new clinical data at ESCRS that reinforces the proven performance of our TECNIS platform – delivering reliable, high-quality visual outcomes tailored to cataract patients’ everyday needs, and enhancing lives through exceptional vision,” said Jacqueline Henderson, President Vision EMEA, Johnson & Johnson. “At Johnson & Johnson, we’re constantly seeking to redefine what’s possible in cataract care – and remain committed to empower surgeons with precision-driven solutions that support personalised care across a diverse range of refractive profiles and lifestyles.”

Featured presentations highlighting the TECNIS platform’s family of premium IOLs:

  • Visual and Refractive Outcomes in Patients with a History of Previous Laser Vision Correction Undergoing Implantation of a Refractive Partial Range of Field Extended Intraocular Lens: Presented by Mr. Stephen Stewart on Sunday, 14 September 2025 at 09:15-10:45 CET
    • This new, refractive partial range of field extended IOL offered a good range of vision, minimal side effects, and high patient satisfaction for those with prior refractive surgery.1
    • Further analysis with be reported at the conference on previous hyperopic or myopic surgery type and results from an additional 30 bilateral LVC patients at three months.1
       
  • Comparison of Visual Outcomes and Defocus Curves Between the Purely Refractive Partial Range of Field Extended IOL TECNIS PureSee™ IOL and the TECNIS™ 1-Piece IOL: Presented by Dr Helena Noguera on Monday, 15 September 2025 at 14:15-15:45 CET
    • The TECNIS PureSee™ IOL provided superior intermediate and near vision without compromising distance vision and maintained a more stable defocus curve compared to the monofocal IOL.2
    • No halos or glare were reported in either groups despite theoretical risks about photopic disturbances.2 
       
  • Tolerance to Induced Astigmatism Amongst Various Intraocular Lenses Categories: Presented by Karolinne Rocha M.D. Ph.D on Monday, 15 September 2025 at 09:15-10:45 CET
    • The TECNIS™ IOL portfolio was evaluated for tolerance to astigmatism across standard monofocal, enhanced monofocal, diffractive EDOF and diffractive multifocal IOLs.3
    • Findings showed better tolerance to induced oblique and against-the-rule astigmatism in the enhanced monofocal IOL group compared to the other types.3
    • Overall, with-the-rule astigmatism was better tolerated than oblique and against-the-rule in all groups.3
       
  • Systematic Review and Meta-Analysis of Enhanced versus Monofocal Intraocular Lenses in Cataract Surgery: E-poster. Dr Joaquin Fernandez.
    • This meta-analysis revealed high-certainty evidence that TECNIS Eyhance™ IOL enhances intermediate and near visual acuity versus standard monofocal IOLs.4
    • Evidence for contrast sensitivity and patient-reported outcomes was moderate to low, with further research needed on other new enhanced monofocal IOLs to confirm their outcomes in comparison to TECNIS Eyhance™ IOL.4

In addition to its scientific presentations, Johnson & Johnson will participate in interactive educational forums and events during ESCRS, including:

  • J&J Vision IOL Innovation Summit: TECNIS Odyssey™ IOL & TECNIS PureSee™ IOL. 12 September at 19:00-20:30 CET. Location: Crown Plaza Ground Floor Everest. Room 3.
  • Vision Beyond Limits: Meet the EDOF Experts: 13 September at 10:30-11:00 CET. Location: Johnson & Johnson Stand E.040 - Bella Congress Centre.
  • Innovating Clarity: Freeform Technology for High Spectacle Independence: 13 September at 13:00-14:00 CET. Location: Bella Congress Centre Room D4.
  • A Quest for High Spectacle Independence: 13 September at 15:00-15:30 CET. Location: Johnson & Johnson Stand E.040 - Bella Congress Centre.
  • Innovating Patient Care: The Clinical Advantages and Economic Impacts of an Enhanced Monofocal IOL: 14 September at 10:30-11:00 CET. Location: Johnson & Johnson Stand E.040 - Bella Congress Centre.
  • TECNIS™ IOL COMPASS: Exploring Technology and Navigating Supreme Patient Care: 14 September at 13:00-14:00 CET. Location: Bella Congress Centre. Room D5.
  • Tips and Tricks for Best SILK™ Practices: 14 September at 15:00-15:30 CET. Location: Johnson & Johnson Stand E.040 - Bella Congress Centre.

####

About TECNIS™ Platform
At Johnson & Johnson, quality begins with the platform. The TECNIST platform uses a proprietary combination of materials and design to deliver more for patients – more clarity with lower reflectance/lower dispersion vs competitor platform5,6,7*, the lowest level of chromatic aberration available on the market8**, and almost complete elimination of spherical aberration.9,10 The TECNIS portfolio also delivers more image contrast - day and night - than the leading competitor platform6,11 *** and more stability to stand the test of time.12,13,14**** Finally, TECNIS delivers more choice for surgeons and patients - offering the broadest portfolio of IOLs, with solutions for every vision need, across a variety of different visual conditions and lifestyles.15

About Vision at Johnson & Johnson 
Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients' eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionising the way people see and experience the world. Visit us at jnjvisionpro.eu and follow Johnson & Johnson | Vision EMEA on LinkedIn.

About Johnson & Johnson 
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to TECNIS™ IOL platform. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realised or may take longer to realise than expected; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

The promoted product is a medical device. For Healthcare Professionals Only. Please reference the Instructions for Use for a complete list of Indications and Important Safety Information and contact our specialists in case of any question.

Footnotes

*Competitor platforms included are Hoya, Alcon &; B&L Acrylic a
**Against IOLs that use Hoya, Alcon Acrylic, and B&;L Silicone 
***Against AcrySof IOL &; Clareon IOL
****Against Acrysof IOL

References 

  1. Stewart S et al. Visual and refractive outcomes in patients with a history of previous laser vision correction undergoing implantation of a refractive partial range of field extended intraocular lens.]
  2. Noguera H et al. Comparison of visual outcomes and defocus curves between the purely refractive partial range of field extended IOL Tecnis PureSee IOL and the Tecnis Monofocal IOL.]
  3. Rocha K et al. Comparison of tolerance to induced astigmatism with a full range of vision, EDOF and monofocal IOL categories]
  4. Fernández J et al. Systematic review and meta-analysis of enhanced versus monofocal intraocular lenses in cataract surgery.]
  5. Zhao H, Mainster MA. Br J Ophthalmol. 2007; 91:1225–1229.
  6. Negishi K et al. Arch Ophthalmol 2001;119:1154-1158.
  7. Krader CG.EUROTIMES 2011/2012;16/17: 18.
  8. Data On File, DOF2018CT4007, Johnson & Johnson Surgical Vision, Inc. 2018
  9. Piers P, Manzanera S, Prieto P, Gorceix N, Artal P. Use of adaptive optics to determine the optimal ocular spherical aberration. J Cataract Refract Surg. 2007 Oct;33(10):1721-6 2.
  10. Data On File, Johnson & Johnson Surgical Vision, Inc. 2015.
  11. Data on File, DOF2018OTH 4004 Johnson & Johnson Surgical Vision, Inc. 2018. (Modular transfer function (MTF) is a measure of the amount of contrast transferred by the optics in a visual system. The higher the MTF value, the more contrast transferred to the image, resulting in higher image contrast.)
  12. Nagata M, Matsushima H, Mukai K, Terauchi W, Senoo T, Wada H, Yoshida S. Clinical evaluation of the transparency of hydrophobic acrylic intraocular lens optics. J Cataract Refract Surg. 2010 Dec;36(12):2056-60.
  13. Van der Mooren M, Franssen L, Piers P. Effects of glistenings in intraocular lenses. Biomed Opt Express.
  14. Auffarth GU, et al. Analysis of optical purity and optical quality of a new extended range of vision IOL. Poster presented at: The 20th ESCRS Winter Meeting; February2016, Athens, Greece.
  15. Freeman W. Market Scope - 2017 IOL report: a global market analysis for 2016 to 2022. P. 79, 137, 174. REF2018MLT4002

Media contact: 
Sarah Smith 
[email protected] 
+44 7920 082012